However, we have to underline that the ORAL Surveillance trial was a non-inferiority trial designed to assess the safety of tofacitinib compared with a TNF inhibitor in RA-active patients, despite methotrexate treatment, aged higher than 50 years and with at least one additional cardiovascular risk factor. Here, TNF is linked to rheumatoid arthritis.